Deals
Novartis and Unnatural Products did not specify which disease targets they’re going after, only noting that the latter’s macrocyclic platform can generate potentially next-generation therapies that could apply to cardiovascular conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
April springs up with showers of cash for these life sciences companies.
The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.
Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.
Under the terms of the deal, Amgen is buying all outstanding shares of Rodeo with a $55 million upfront payment. In addition, there are potential milestone payments that could hit $666 million in cash.
Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.
This morning, Ikena Oncology, Design Therapeutics and Edgewise Therapeutics began trading on the exchange.
Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
It’s been another strong week of biopharma companies making their debut on a stock exchange. Over the past 48 hours, three companies, Finch Therapeutics, Connect Biopharma and Gain Therapeutics, all made their debut on the Nasdaq.